Nicolas Wolikow, Co-founder & CEO, Cure51 | Slush 2025
summary
Cure51 collects the rare <1% “exceptional survivors” from 55+ countries and 100+ hospital partners, imports tumor tissue to a Paris biobank and runs advanced single‑cell sequencing to decode survival biology. A target‑explorer platform classifies signals and an AI‑driven lab‑in‑the‑loop accelerates validation; teams already nominate two novel pancreatic targets discovered in under three months and plan biotech/pharma partnerships to turn hits into drugs. Claim: this pipeline can scale to discover many targets and aim to help eradicate cancer within 15 years.
AI-written summary · about
related talks
35mUsing Large-Scale Clinico-Genomics Data for in silico Clinical Trials and Precision Oncology
20mTranslating a Trillion Pointo Diseases of Data into Therapies
34mFrom Data to Discovery: How AI Is Finding Hidden Cures
50mThe algorithm for precision medicine
10mGenesis Final Round - Drylab AI
44mNext-Gen Therapies
16mHow Biology Benefits from Technological Discoveries
37mHow Developers can treat Ovarian Cancer